FLFrancesca Lanzaro

Francesca Lanzaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesca Lanzaro has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Pierluigi Marzuillo

    Department of Woman, Child and of General and Specialized Surgery, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy

    2 shared publications
  • A. Di Giannatale

    Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

    1 shared publication
  • A. Mastronuzzi

    Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

    1 shared publication
  • Anna Di Sessa

    Department of Woman, Child, and General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, Naples, Italy

    1 shared publication
  • Annalisa Serra

    Area of Hematology‐Oncology, Cell Therapy, Gene Therapies, and Hematopoietic Transplantation Bambino Gesù Children's Hospital IRCCS Rome Italy

    1 shared publication
  • C. Altini

    Nuclear Medicine Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

    1 shared publication

Latest Publications

  • Open Access

    131I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future

    by M.A. De Ioris, M.F. Villani, F. Fabozzi, F. Del Bufalo, C. Altini, M.G. Cefalo, V. Cannata, G. Del Baldo, M. Pizzoferro, I. Alessi, et al.


  • Open Access

    Childhood Multiple Endocrine Neoplasia (MEN) Syndromes: Genetics, Clinical Heterogeneity and Modifying Genes

    by Francesca Lanzaro, Delia De Biasio, Francesco Giustino Cesaro, Emanuela Stampone, Immacolata Tartaglione, Maddalena Casale, Debora Bencivenga, Pierluigi Marzuillo, Domenico Roberti

    Multiple endocrine neoplasia (MEN) syndromes are part of a spectrum of clinically well-defined tumor syndromes ultimately characterized by histologically similar tumors arising in patients and families with mutations in one of the following four genes: MEN1, RET, CDKN1B, and MAX. The high level of genetic and phenotypic heterogeneity has been linked to phenocopies and modifying genes, as well as unknown mechanisms that might be investigated in the future based on preclinical and translational considerations. MEN1, also known as Wermer’s syndrome (OMIM *131100), is an autosomal dominant syndrome codifying for the most frequent MEN syndrome showing high penetrance due to mutations in the MEN1 gene; nevertheless, clinical manifestations vary among patients in terms of tumor localization, age of onset, and clinical aggressiveness/severity, even within the same families. This has been linked to the effect of modifying genes, as described in the review. MEN 2-2b-4 and 5 also show remarkable clinical heterogeneity. The traditional view of genetically predisposing monogenic or multifactorial disorders is no longer valid, and mandates a change in scientific focus. Phenotypes are indeed rarely consistent across genetic backgrounds and environments. In the future, understanding factors and genetic variants that control cellular functions and the expression of disease genes should provide insights into fundamental disease processes, providing implications for counseling and therapeutic and prophylactic possibilities.


  • Open Access

    COVID-19 and pediatric fatty liver disease: Is there interplay?

    by Anna Di Sessa, Francesca Lanzaro, Sarah Zarrilli, Vittorio Picone, Stefano Guarino, Emanuele Miraglia del Giudice, Pierluigi Marzuillo

    The rapid global spread of coronavirus disease 2019 (COVID-19) infection has become a major health issue with higher morbidity and mortality rates. Besides respiratory symptoms, a growing body of evidence indicates a variety of gastrointestinal manifestations including liver involvement. In this regard, several data supported an association between COVID-19 infection and liver injury in adults, while in children there is compelling but currently limited evidence. In particular, patients with COVID-19 have shown a higher risk of liver injury (mainly expressed as increased transaminase levels or hepatic steatosis). Conversely, a greater risk of more severe forms of COVID-19 infection has been observed in subjects with pre-existing chronic liver diseases. The dramatic interplay between COVID-19 and liver damage has been related to the inflammatory pathways chronically active in patients with nonalcoholic fatty liver disease and acutely in those affected by COVID-19, but other different pathogenic mechanisms have also been supposed. Of note, patients with previous metabolic comorbidities also had a higher risk of severe COVID-19 infection. This emphasizes the pathogenic interrelation of the inflammatory pathways with a dysregulated metabolic milieu in COVID-19 patients. Taking into account the prognostic role of fatty liver in COVID-19 patients and its intrinsic relationship with metabolic abnormalities even in childhood, a strict monitoring of this condition is recommended. We aimed to summarize the most recent evidence regarding the potential interplay between pediatric fatty liver and COVID-19.